Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Climb Bio (CLYM) Equity Average (2020 - 2026)

Climb Bio filings provide 7 years of Equity Average readings, the most recent being $154.3 million for Q1 2026.

  • Quarterly Equity Average fell 23.86% to $154.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $154.3 million through Mar 2026, down 23.86% year-over-year, with the annual reading at $186.2 million for FY2025, 16.55% up from the prior year.
  • Equity Average hit $154.3 million in Q1 2026 for Climb Bio, down from $168.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $220.5 million in Q3 2024 and bottomed at $107.0 million in Q1 2024.
  • Average Equity Average over 5 years is $155.3 million, with a median of $154.3 million recorded in 2026.
  • The largest annual shift saw Equity Average surged 572.89% in 2022 before it fell 23.86% in 2026.
  • Climb Bio's Equity Average stood at $131.5 million in 2022, then fell by 17.38% to $108.7 million in 2023, then soared by 98.15% to $215.3 million in 2024, then dropped by 21.64% to $168.7 million in 2025, then fell by 8.57% to $154.3 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Equity Average are $154.3 million (Q1 2026), $168.7 million (Q4 2025), and $181.4 million (Q3 2025).